Clinical trial

Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Name

assiut hospitals university

Description

assessment of inflammatory bowel disease patients in activity and remission by abdominal ultrasound examine non-invasive and in physiological condition by measuring the colon wall thickness in diagnosis and follow up the patient also including extra intestinal features such as the splanchnic vessels,mesentery and lymph nodes . Doppler u.s can evaluate bowel wall vascularity In activity and remission . peripheral hemogram in relationship to activity inflammatory bowel disease asses anemia ,increase monocyte and decrease mean platelet volume( MPV) . also,the investigator will evaluate the outcome of different lines of treatment traditional and biologic therapy (response to treatment,times of activity and complications)

Trial arms

Trial start

2018-07-01

Estimated PCD

2021-02-01

Trial end

2021-10-01

Status

Completed

Treatment

Infliximab

follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy

Arms:

patient on infliximab, patient on traditional therapy

Other names:

steroid,immuran 5ASA

Size

Primary endpoint

the role abdominal ultrasound in assessment inflammatory bowel disease

2 year

Eligibility criteria

Inclusion Criteria * patients diagnosed ulcerative colitis at age(15-60) * patients diagnosed crohns disease at age(15-60)k Exclusion criteria * liver cirrhosis and portal hypertension * spontaneous bacterial peritonitis * Ischemic colitis

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '1 Year', 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 60, 'type': 'ACTUAL'}}

Updated at

2023-08-29

1 organization

1 product

1 indication

Organization

Assiut University

Product

Infliximab

Indication

Inflammatory Bowel Disease